FY2025 Earnings Estimate for Agenus Issued By HC Wainwright

Agenus Inc. (NASDAQ:AGEN) – Research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Agenus in a report released on Tuesday, November 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $2.09 per share for the year, up from their previous estimate of $0.03. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q4 2025 earnings at $1.54 EPS, FY2026 earnings at ($1.53) EPS, FY2027 earnings at ($1.69) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.61) EPS.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The business had revenue of $30.24 million for the quarter, compared to analyst estimates of $80.39 million.

A number of other brokerages have also weighed in on AGEN. Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a research report on Sunday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Agenus in a research note on Wednesday, October 8th. Finally, Zacks Research raised Agenus to a “hold” rating in a research report on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Agenus presently has an average rating of “Hold” and an average target price of $14.50.

Agenus Stock Down 0.7%

Shares of AGEN traded down $0.03 during trading hours on Thursday, hitting $4.40. The company had a trading volume of 85,988 shares, compared to its average volume of 726,188. The firm has a market cap of $140.20 million, a P/E ratio of -0.62 and a beta of 1.43. Agenus has a 52-week low of $1.38 and a 52-week high of $7.34. The stock’s 50 day moving average price is $4.18 and its 200 day moving average price is $4.50.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Agenus by 1.5% in the third quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock worth $9,893,000 after acquiring an additional 36,983 shares during the period. Siren L.L.C. purchased a new stake in Agenus during the 1st quarter valued at $752,000. AQR Capital Management LLC lifted its position in Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after buying an additional 427,604 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Agenus in the second quarter valued at $1,976,000. Finally, Bank of America Corp DE lifted its holdings in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 220,327 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.